Skip to main content

ondansetron

Generic: ONDANSETRON·Brand: ONDANSETRON, ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER, ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ZOFRAN, ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER, ZOFRAN ODT, ZOFRAN PRESERVATIVE FREE, ZUPLENZ, Zuplenz

ondansetron: developed by 1 company · 5 clinical trials tracked.

ondansetron evidence translation

What we can confirm

What it means

Source-backed records connect ondansetron to ADIL; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could ondansetron → ADIL affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence3 indications · 5 study sponsors
Development Pipeline (1)
Clinical Trials (5)

A Phase 4, Randomized, Open Label Study to Evaluate the Safety and Tolerability of Twice Daily Xanomeline/Trospium Chloride (KarXT) With Prophylactic and PRN Antiemetic Use in Healthy Volunteers

NCT07681076·Phase 4·BMY
Not yet recruiting

Primary endpoint: Number of participants with Treatment Emergent Adverse Events (TEAEs)

InterventionalRandomizedopen225 targetStarted 2026-08Completion 2026-11Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Comparative Effectiveness of Routine Antiemetic Prophylaxis in Nonfasted Parturients Undergoing Cesarean Sections Under Spinal Anesthesia: A Prospective Randomized Controlled Trial

NCT07740577·Phase 4·GHRS
Recruiting

Primary endpoint: Incidence of Intraoperative Nausea and Vomiting Immediately After Fetal Delivery

InterventionalRandomizeddouble100 targetStarted 2026-07Completion 2027-011 site · Turkey (Türkiye)Sanliurfa Education and Research Hospital

Continuous Infusion of First-Generation 5-HT3 Receptor Antagonists in Combination With Dexamethasone. Can This Modality Improve the Antiemetic Effect

NCT05872893·Phase 3·IMNP
Completed

Primary endpoint: Mean nausea score per patient

InterventionalRandomizedsingle28 enrolledStarted 2023-06Completion 2025-011 site · ArmeniaImmune Oncology Research Institute

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

Recruiting

Primary endpoint: M/P ratio

Observational1,600 targetStarted 2018-10Completion 2027-0722 sites · Canada, United StatesDuke University

A Phase 3 Clinical Study Protocol: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Study of APF530 500 mg SC, Fosaprepitant 150 mg IV, and Dexamethasone vs. Ondansetron 0.15 mg/kg IV, Fosaprepitant 150 mg IV, and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy

NCT02106494·Phase 3·HRTX
Completed

Primary endpoint: Delayed Phase Complete Response (CR) Rate

InterventionalRandomizedquadruple942 enrolledStarted 2014-03Completion 2015-057 sites · United StatesHeron Therapeutics

Frequently asked questions

Who is developing ondansetron?

ondansetron is being developed by ADIAL PHARMACEUTICALS, INC..

How many clinical trials involve ondansetron?

BioSniper tracks 5 clinical trials involving ondansetron.